(S)-1-Boc-3-hydroxypiperidine: A Crucial Pharmaceutical Intermediate
Explore the synthesis and applications of this vital chiral building block in modern drug development.
Get a Quote & SampleProduct Core Value
(S)-1-Boc-3-hydroxypiperidine
This chiral intermediate plays a pivotal role in the synthesis of high-value pharmaceuticals, most notably Ibrutinib, a targeted therapy for certain blood cancers. Its precise stereochemistry is essential for the efficacy and safety of the final drug product.
- Leveraging synthesis of ibrutinib intermediate, we provide a critical component for advanced oncology treatments.
- As a key chiral intermediate for lymphoma treatment, its availability supports the production of life-saving medications.
- Discover the versatility in s-1-boc-3-hydroxypiperidine uses beyond Ibrutinib, serving as a versatile building block for novel drug candidates.
- The development of biocatalytic synthesis of s-nbhp highlights our commitment to green chemistry and efficient manufacturing processes.
Key Advantages Offered
Enhanced Bioactivity
The chiral hydroxyl group at the C3 position significantly influences the bioactivity of molecules derived from this intermediate, making it ideal for targeted drug design. This is crucial for achieving desired outcomes in pharmaceutical intermediate cas 143900-44-1 applications.
Efficient Synthesis Pathways
Both chemical and enzymatic synthesis methods are well-established, offering flexibility and efficiency in production. The adoption of biocatalytic synthesis of s-nbhp further streamlines manufacturing, reducing environmental impact.
Critical for Oncology Drugs
Its indispensable role in the synthesis of ibrutinib intermediate makes it a cornerstone for therapies treating conditions like chronic lymphocytic leukemia and mantle cell lymphoma.
Key Applications
Pharmaceutical Synthesis
Serves as a fundamental chiral building block for a wide array of active pharmaceutical ingredients (APIs), enabling precise molecular construction in drug discovery. This is central to its function as a pharmaceutical intermediate cas 143900-44-1.
Ibrutinib Production
A non-negotiable component in the multi-step synthesis of Ibrutinib, a critical drug for treating B-cell malignancies, underscoring its importance in targeted cancer therapy. The focus on the synthesis of ibrutinib intermediate highlights its market value.
Chiral Drug Development
Facilitates the development of other chiral drugs by providing a reliably synthesized chiral center, essential for stereospecific interactions with biological targets.
Research and Development
Used in academic and industrial research laboratories for exploring new synthetic routes and developing novel therapeutic agents, leveraging its unique chemical structure.